Novartis’ Signifor Seeks Controlled-Data Edge In Cushing Market At Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Cushing’s disease treatment Signifor (pasireotide) underwent a randomized Phase III clinical trial, while the earlier approval of competitor Corcept Therapeutics’ Korlym (mifepristone) was based on an open-label study.